Palvella Therapeutics is a clinical-stage biopharmaceutical company developing topical therapies for rare skin diseases and vascular malformations that currently lack FDA-approved treatments. The company's proprietary QTORIN platform is an anhydrous gel formulation designed to deliver drugs deep into skin tissue with minimal systemic absorption, with lead programs in rapamycin-based treatments for microcystic lymphatic malformations, cutaneous venous malformations, and angiokeratomas, as well as a pitavastatin candidate for a premalignant skin disease. The company plans to commercialize products through a specialty sales force targeting dermatologists and vascular centers, relying on contract manufacturers for supply, while generating revenue from product sales and potentially licensing deals outside the United States.